Predicting response and survival in chemotherapy-treated triple-negative breast cancer
Prat, A. (Universitat Autònoma de Barcelona. Departament de Medicina)
Lluch, Ana ![Identificador ORCID](/img/uab/orcid.ico)
(Hospital Clínic Universitari (València))
Albanell Mestres, Joan ![Identificador ORCID](/img/uab/orcid.ico)
(Universitat Pompeu Fabra)
Barry, W. T. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Department of Biostatistics and Computational Biology)
Fan, C. (University of North Carolina. Lineberger Comprehensive Cancer Center)
Chacón, José Ignacio ![Identificador ORCID](/img/uab/orcid.ico)
(Hospital Virgen de la Salud (Toledo))
Parker, J. S. (University of North Carolina. Department of Genetics)
Calvo, L.. (Complejo Hospitalario Universitario de A Coruña)
Plazaola, A. (Department of Medical Oncology, Onkologikoa)
Arcusa, Àngels (Consorci Sanitari de Terrassa. Departament d'Oncologia Mèdica)
Seguí-Palmer, M. A. (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Burgués, Octavio
(Hospital Clínic Universitari (València))
Ribelles, Nuria
(Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia))
Rodriguez-Lescure, A. (Hospital General Universitario de Elche)
Guerrero, A. (Fundació Institut Valencià d'Oncologia)
Ruiz-Borrego, M. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Munárriz, Blanca (Hospital Universitari i Politècnic La Fe (València))
López, J. A. (Hospital San Camilo)
Adamo, Barbara (Hospital Universitari Vall d'Hebron)
Cheang, M. C. U. (University of North Carolina. Lineberger Comprehensive Cancer Center)
Li, Y (University of North Carolina. Lineberger Comprehensive Cancer Center)
Hu, Z. (University of North Carolina. Lineberger Comprehensive Cancer Center)
Gulley, M. L. (University of North Carolina. Lineberger Comprehensive Cancer Center)
Vidal, M. J. (Hospital Universitari Vall d'Hebron)
Pitcher, B. N. (Alliance Statistical and Data Center, Duke University)
Liu, M. C. (Mayo Clinic. Department of Oncology)
Citron, M. L. (ProHEALTH Care Associates, LLP)
Ellis, Matthew J (Washington University. Department of Oncology)
Mardis, E. (Washington University. Department of Oncology)
Vickery, T. (Washington University. Department of Oncology)
Hudis, C. A. (Memorial Sloan Kettering Cancer Center)
Winer, E. P. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica))
Carey, L. A. (University of North Carolina. Lineberger Comprehensive Cancer Center)
Caballero, Rosalía (Grupo Español de Investigación en Cáncer de Mama)
Carrasco, E. (Grupo Español de Investigación en Cáncer de Mama)
Martín, M. (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))
Perou, Charles M.
(University of North Carolina. Department of Pathology and Laboratory Medicine)
Alba, Emilio
(Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia))
Data: |
2014 |
Resum: |
In this study, we evaluated the ability of gene expression profiles to predict chemotherapy response and survival in triple-negative breast cancer (TNBC). Gene expression and clinical-pathological data were evaluated in five independent cohorts, including three randomised clinical trials for a total of 1055 patients with TNBC, basal-like disease (BLBC) or both. Previously defined intrinsic molecular subtype and a proliferation signature were determined and tested. Each signature was tested using multivariable logistic regression models (for pCR (pathological complete response)) and Cox models (for survival). Within TNBC, interactions between each signature and the basal-like subtype (vs other subtypes) for predicting either pCR or survival were investigated. Within TNBC, all intrinsic subtypes were identified but BLBC predominated (55-81%). Significant associations between genomic signatures and response and survival after chemotherapy were only identified within BLBC and not within TNBC as a whole. In particular, high expression of a previously identified proliferation signature, or low expression of the luminal A signature, was found independently associated with pCR and improved survival following chemotherapy across different cohorts. Significant interaction tests were only obtained between each signature and the BLBC subtype for prediction of chemotherapy response or survival. The proliferation signature predicts response and improved survival after chemotherapy, but only within BLBC. This highlights the clinical implications of TNBC heterogeneity, and suggests that future clinical trials focused on this phenotypic subtype should consider stratifying patients as having BLBC or not. |
Ajuts: |
Instituto de Salud Carlos III PI13-01718
|
Drets: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra, i la creació d'obres derivades, sempre que no sigui amb finalitats comercials i que es distribueixin sota la mateixa llicència que regula l'obra original. Cal que es reconegui l'autoria de l'obra original. ![Creative Commons](/img/licenses/by-nc-sa.ico) |
Llengua: |
Anglès |
Document: |
Article ; recerca ; Versió publicada |
Matèria: |
Breast cancer ;
Genomics ;
Subtypes ;
Intrinsic ;
Basal like ;
Chemotherapy ;
Neoadjuvant |
Publicat a: |
British journal of cancer, Vol. 111 (08 2014) , p. 1532-1541, ISSN 1532-1827 |
DOI: 10.1038/bjc.2014.444
PMID: 25101563
El registre apareix a les col·leccions:
Documents de recerca >
Documents dels grups de recerca de la UAB >
Centres i grups de recerca (producció científica) >
Ciències de la salut i biociències >
Institut d’Investigació i Innovació Parc Taulí (I3PT) Articles >
Articles de recercaArticles >
Articles publicats
Registre creat el 2018-01-29, darrera modificació el 2024-06-11